Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Reliq Health Technologies Inc V.RHT.H

Alternate Symbol(s):  RQHTF

Reliq Health Technologies Inc. is a global healthcare technology company that specializes in developing virtual care solutions for the healthcare market. The Company’s iUGO Care platform supports care coordination and community-based virtual healthcare. iUGO Care allows complex patients to receive care at home, improving health outcomes, enhancing quality of life for patients and families and... see more

TSXV:RHT.H - Post Discussion

View:
Post by theinvestor22 on Jun 02, 2022 3:15pm

Lisa chit chat

I've commented before that, once the company has been de-risked, I expected the focus to shift away from basic viability to valuation.  A corollary to this is that I thought the endless Lisa-related bickering would go away and the negative folks would instead make running commentary on how expensive the stock has become.  I mean, after all, what would be left?
 
Even though I am seeing a bit more discussion of valuation lately, it seems as though I'll have to wait a while longer for the conversation to make the transition, mostly because, while momentum is obviously there, we haven't quite gotten to the point where the company is undeniably and irrevocably profitable.
 
Either that, or I was completely wrong.
 
Right now, it seems there are 2 camps - those who mostly focus on what Lisa has said and those who are mostly concerned with the progress of the company itself.  As everyone knows by now, I fall into that latter group, and with good reason.  The company will either make it, or it won't.  (I think it will.)  The superficial stuff, like Lisa's ability to estimate or hype will have little to do with it in the end.
 
As I mentioned yesterday, from a numbers perspective, there is a clear indication of progress.  Add that to the posting I made earlier regarding the extra one-time R&D in fiscal Q3 accounting for 92% of the loss for the quarter, and it becomes obvious that the company is approaching the break-even point.
 
So, will the Lisa-related chatter end once the growth curve become permanently entrenched?  I can't say for sure, but I do think the chatter will become more irrelevant than it already is.  
 
Much to look forward to.
Comment by lscfa on Jun 02, 2022 6:34pm
  Patients 100,000 200,000 Revenue @ $50 cdn 60,000,000 120,000,000 45% ebitda  27,000,000 54,000,000 Shs diluted 205,000,000 205,000,000  ...more  
Comment by aaaaaargh on Jun 03, 2022 12:47am
Thanks alot Iscfa.   You made me spray my drink all over.  Hilarious.  You have to include the Lisa B/S discount in all of your future tables.....lol. 
Comment by throwin on Jun 06, 2022 7:19pm
So funny aaaargggh. You and your bashing buddy Iscfa are the biggest troll, non shareholders on this board. Two clowns talking to each other.... honk honk
Comment by mjh9413 on Jun 07, 2022 10:30am
This chit chat is serious stuff. Let's recap: Lisa had no relevant CEO experience up to the time she joined Reliq, show me otherwise. She has consistently not informed and misinformed on the company's contracts and performance and actual active client numbers She is one of 3, yes just 3 directors, none of which is truly independant, just a triumvirate and no control over executive actions ...more  
Comment by Stocker46 on Jun 07, 2022 10:48am
Don't know if you own shares ... if you do, I would strongly suggest you sell them & move on ... if you don't, why are you here incessantly bashing RHT?
Comment by theinvestor22 on Jun 07, 2022 2:47pm
Let's just take stock of where the company is: - Some said former problem employees would destroy the company.  Not true.  And those former employees paid Reliq compensation. - Some complained the company wouldn't be able to sign contracts since their troubles.  Not true.  199 contracts according to my count and new ones being added weekly. - I recall statements that ...more  
Comment by lscfa on Jun 07, 2022 5:28pm
Some said the guidance of $11 million revenue in 2021 would not be met and they were right.      Some now say the $40 million revenue guidance for 2022 will not be met and co. has stopped reiterating that no.  
Comment by aaaaaargh on Jun 07, 2022 10:22pm
Why in all things holy, do you think that showing annualized revenue numbers that clearly show that once again reliq is absolutely nowhere on pace to hit their guidance....is a positive???  Fascinating.
Comment by vitalina2233 on Jun 07, 2022 3:17pm
9413   since your to gutless to send your b.s. concerns to IR  Scott  I took the liberty to send your post . Will post when he replys, as i said in your post... if he needs to reply to a basher on a bullboard. My asst Peggy will get the reply then send it to me  Papi
Comment by mjh9413 on Jun 07, 2022 3:38pm
GUTLESS?  Not sending  a note to IR is gutless? I don't know hw you ratonalise your position or statements. And I say, what is the point. They provide qtly results which are less than their prior promises, don't give enough deetail to know exactly what is happening, and you take this as satisfactory...well writing to the company will yield nothing more than they do in a webinar ...more  
Comment by vitalina2233 on Jun 07, 2022 5:43pm
why didn't you send it to IR   What the heck is posting on the board going to solve   SFA   Lets see if scott replies before we get into it  Papi
Comment by theinvestor22 on Jun 07, 2022 8:57pm
A bit of a mistake in this posting.  Statements about the future from companies are not promises.  They are estimates.
Comment by mjh9413 on Jun 03, 2022 12:59am
Yes, forget Lisa and let's talk numbers. $2MM/mth means averaging ~38000 clients per mth contributing C$55 monthly (that's a fair $ amount as I am never sure if amounts from RHT NR's are net or not) To get to $40MM revs in fy2022  they need to average ~60,000 paying clienst every month. Do you think we will see 60,000 average clients per month any time this year given the first ...more  
Comment by lscfa on Jun 03, 2022 8:14am
BiSa says 100,000 patients by yearend.     Qtr ending Mar 22 Jun 22 Sept 22 Dec 22 Total Patients beginning   40,000 60,000 80,000    ...more  
Comment by 3burtc on Jun 03, 2022 8:25am
We are close to 100 000 already. Why do you think Data Soft wasn't onboarding until after the update. So now you can pretend a little more. D. A.
Comment by mjh9413 on Jun 03, 2022 8:42am
3burtc where did you get your number from? Wud equal over $60MM in FTM! eom
Comment by 3burtc on Jun 03, 2022 11:08am
I've been going over the contracts from 2022 and watching jack & lisa's videos from this year. Add in the bullish comments from Lisa ( "we are onboarding at a rapid pace"), 40000 patients at Dec 31/2021. Now include Data soft Logic at 30 to 40 thousand patients the first month, and you are easily at 100000 before the year is half over. Remember Lisa said the large ...more  
Comment by lscfa on Jun 03, 2022 8:28am
Co. did not reiterate revenue guidance in NR or CC.    I suspect the $40 million for calender 2022 will not be met.      
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities